Community oncology practices say they are recovering from the COVID-19 pandemic and keeping their eye on the goal of value-based care. The strategies they are using to accomplish these initiatives include innovation, long-term integration of telehealth, and the leveraging of advanced practice professionals.
Despite current interventions, chemotherapy‐induced myelosuppression can result in a range of
different adverse events—neutropenia, anemia, and thrombocytopenia. Given the challenges health
systems are now facing, more healthcare visits can create management challenges and additional
burden on patients. Hear what Dr. Jeffrey Crawford (Medical Oncologist) has to say about the ongoing
challenges of myelosuppression and hematopoietic stem and progenitor cell (HSPC) damage during